title: Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.
abstract: Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years. In two, randomized, double-blind, placebo-controlled studies in pediatric patients aged 6-17 years with irritability associated with autistic disorder, 8 weeks of treatment with aripiprazole 2-15 mg/day, compared with placebo, resulted in significant improvements in the Aberrant Behavior Checklist Irritability subscale score at endpoint (primary endpoint), and the mean Clinical Global Impression-Improvement score. Aripiprazole was generally well tolerated in this patient population in the two 8-week studies and a 52-week study, with most adverse events being mild to moderate in severity. Aripiprazole was associated with weight gain in both the short- and long-term studies; data from the long-term study indicated that the increase in bodyweight reached a plateau at 3-6 months.
authors.affiliation: Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Monique P
authors.initials: MP
authors.lastname: Curran
mesh_terms: D000068180:Aripiprazole; D001321:Autistic Disorder / Q000150:complications*; D002648:Child; D002986:Clinical Trials as Topic; D054796:Drug Dosage Calculations; D006801:Humans; D007508:Irritable Mood / Q000187:drug effects*; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole